U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449/PTO  INFORMATION DISCLOSURE STATEMENT BY APPLICANT				re required to respond to a collection of information unless it contains a valid OMB control number.  Complete if Known		
				Application Number	09/955,367	
				Filing Date	09/18/2001	
				First Named Inventor	Alan D. Attie	
(Use as many sheets as necessary)			acass sm/l	Art Unit	1634	
			acossary)	Examiner Name	Diana B. Johannsen	
Sheet	1	of	1	Attorney Docket Number	960296.97478	

Examiner	Cite	OTHER PRIOR ART-NON PATENT LITERATURE DOCUMENTS			
examiner Initials*	No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			
DBJ		Choo,H.J., et al., "Mitochondria are impaired in the adipocytes of type 2 diabetic mice," Diabetologia 48:784-791 (2006)			
		Ducluzeau, P-H., et al., "Regulation by Insulin of Gene Expression in Human Skeletal Muscle and Adipose Tissue," Diabetes 50:1134-1142 (2001)			
		Sewter, C., et al., "Human Obesity and Type 2 Diabetes are Associated with Alterations in SREBP1 Isoform Expression That are Reproduced," Diabetes 51:1035-1041 (2002)			
		Shimomura, I., et al., "Nuclear Sterol Regulatory Element-binding Proteins Activate Genes Responsible for the Entire," J. Biol. Chem. 273:35299-35306 (1998)(abstract)			
$\bigvee$		Yang, X., et al., "Evidence of Impaired Adipogenesis in Insulin Resistance," Biochem Biophys Res Commun 14:317(4):1045-51 (2004)(abstract)			
DBJ		Yki-Jarvinen, H., "Role of insulin resistance in the pathogenesis of NIDDM," Diabetologia 38:1378-88 (1995)(astract)			
,					
······································					

Examiner		Date	10/30/2006	ı
Signature	/Diana B. Johannsen/	Considered	10,30,2000	ı

'EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450.

ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.